## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:	) Group Art Unit: 1648
Martin Leonard Ashdown	Confirmation No.: 8112
Serial No.: 10/576,981	) Examiner: Zachariah Lucas
Filed: March 2, 2007	)
Atty. File No.: 5517-18	) <u>INFORMATION DISCLOSURE</u>
Entitled: "Method of Therapy"	) <u>STATEMENT</u>
	) Electronically Submitted
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	
Dear Sir:	
of the Examiner.  Copies of the cited non-patent and/or for Copies of the cited U.S. patents and/or patents and/or patents of the cited U.S. patents/patent accordance with 37 C.F.R. § 1.98(a).  Copies of the cited references are not § 1.98(d), because the references were cited Trademark Office in prior application Serial Not which is relied upon for an earlier filing date under the company of the cited application serial Not which is relied upon for an earlier filing date under the cited application serial Not which is relied upon for an earlier filing date under the cited and company of the cited upon for an earlier filing date under the cited upon for an earlier filing date under the cited upon for an earlier filing date under the cited upon for an earlier filing date under the cited upon for an earlier filing date under the cited upon for an earlier filing date under the cited upon for an earlier filing date under the cited upon for an earlier filing date upon for an earli	patent applications are enclosed herewith. application publications are not enclosed in of enclosed, in accordance with 37 C.F.R. by or submitted to the U.S. Patent and of
To the best of applicants' belief, the pe	ertinence of the foreign-language references
are believed to be summarized in the attached I	
applicants do not necessarily vouch for the accu	•
Examiner's attention is drawn to the fol	C 11
	8/08 (Attorney's Ref. No. 5517-22-CON)
	08/05 (Attorney's Ref. No. 5517-23)
<u></u>	(14/07 (Attorney's Ref. No. 5517-26-PUS)
Other:	
Submission of the above information is	not intended as an admission that any item

Submission of the above information is not intended as an admission that any item is citable under the statutes or rules to support a rejection, that any item disclosed represents analogous art, or that those skilled in the art would refer to or recognize the

pertinence of any reference without the benefit of hindsight, nor should an inference be drawn as to the pertinence of the references based on the order in which they are presented. Submission of this statement should not be taken as an indication that a search has been conducted, or that no better art exists.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application and the references made of record therein.

## **FEES**

37 CFR 1.97(b): No fee is believed due in connection with this submission, because the information disclosure statement submitted herewith is satisfied by one of the following conditions ("X" indicates satisfaction):  Within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d), or  Within three months of the date of entry into the national stage of an international application as set forth in 37 CFR 1.491 or  Before the mailing date of a first Office Action on the merits, or  Before the mailing of a first Office action after the filing of a request for continued examination under 37 CFR 1.114.  Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970.
37 CFR 1.97(c): The information disclosure statement transmitted herewith is being filed after all the above conditions (37 CFR 1.97(b)), but before the mailing date of one of the following conditions:  (1) a final action under 37 C.F.R. 1.113 or  (2) a notice of allowance under 37 C.F.R. 1.311, or  (3) an action that otherwise closes prosecution in the application.  This Information Disclosure Statement is accompanied by:  A Certification (below) as specified by 37 C.F.R. 1.97(e). Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970.  OR  Please charge Deposit Account 19-1970 in the amount of \$180.00 for the fee set forth in 37 C.F.R. 1.17(p) for submission of an information disclosure statement. Please credit any overpayment or charge any underpayment to Deposit Account 19-1970.
37 CFR 1.97(d): This Information Disclosure Statement is being submitted after the period specified in 37 CFR 1.97(c).  This information Disclosure Statement includes a Certification (below) as specified by 37 C.F.R. 1.97(e)  AND  Applicants hereby requests consideration of the reference(s) disclosed herein. Please charge Deposit Account 19-1970 in the amount of \$180.00 under 37 C.F.R. 1.17(p). Please credit any overpayment or charge any underpayment to Deposit Account 19-1970. Election to pay the fee should not be taken as an indication that applicant(s) cannot execute a certification.

,	Certification (37 C.F.R. 1.97(e)) (Applicable only if checked)
	(Applicable only if theckett)
	The undersigned certifies that:  Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(1).  A copy of the communication from the foreign patent office is enclosed.
	OR
	No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(2).
	Respectfully submitted,
	SHERIDAN ROSS P.C.

Robert D. Traver

(303) 863-9700

Registration No. 47999 1560 Broadway, Suite 1200

Denver, Colorado 80202-5141

Date: 25 Nov Zoog